<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The six-transmembrane epithelial antigen of prostate (STEAP) protein was identified in advanced <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> and is up-regulated in <z:e sem="disease" ids="C0346429" disease_type="Neoplastic Process" abbrv="">multiple cancer</z:e> cell lines, including prostate, bladder, colon, ovarian, and Ewing <z:hpo ids='HP_0100242'>sarcoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>STEAP1 was described as a suitable antigen for T-cell-based or antibody-based immunotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>We have investigated the expression of STEAP1 in 40 human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types - brain, epithelial, lymphoid - and in their <z:mpath ids='MPATH_458'>normal</z:mpath> tissue counterparts using publicly available gene expression data, including the Oncomine <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Microarray database </plain></SENT>
<SENT sid="3" pm="."><plain>STEAP1 was found significantly overexpressed in 11 cancers </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, high STEAP1 expression was associated with poor overall survival in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Taken together, these data suggest that STEAP1 is a potential therapeutic target for T-cell based immunotherapy or antibody therapy in a large panel of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>